Columbia Care (CCHWF)

Overall impact
C (59)

Commentary

Columbia Care is an average overall performer. With a 'C' rating of 59.4 for overall impact (61st percentile compared to all companies), Columbia Care ranks 112th out of 154 industry peers, behind Adamis Pharmaceuticals, Benitec Biopharma, Aquinox Pharmaceuticals and 108 others, and ahead of Evolus, Oyster Point Pharma, Lupin and 39 others. On top material causes for Columbia Care's industry (Pharmaceuticals & Biotech), Columbia Care performs well in Disease Eradication (96.6 score), Child and Maternal Health (93.3), Access to Affordable Healthcare (96.0) and 3 other causes where it received an 'A' score and performs poorly in Racial Justice and Civil Rights (18.1 score), Fair Labor Practices (6.6), Improved Mental Health (12.3) and 5 other causes where it received a 'D' or 'F' score.
Impact
Cause CCHWF
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2012
Employees
2,505
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ny, United States
Share classes
CCHWF
Description
The Cannabist Company Holdings Inc. engages in the cultivation, manufacture, and provision of cannabis products and related services in the United States and internationally. The company offers spanning flower, edibles, oils, and tablets under the Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber brand names. It holds licenses in 17 jurisdictions in the United States. The company was formerly known as Columbia Care Inc. and changed its name to The Cannabist Company Holdings Inc. in September 2023. The company was founded in 2012 and is headquartered in New York, New York.
Material causes
Ethos considers the following causes material for Columbia Care, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.